产品
编 号：F404322
分子式：C19H22N2S
分子量：310.46
分子式：C19H22N2S
分子量：310.46
产品类型
规格
价格
是否有货
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 60-89-9
产品详情
生物活性：
Mepazine (Pecazine) is a potent and selective MALT1 protease inhibitor with IC50s of 0.83 and 0.42 μM for GSTMALT1 full length and GSTMALT1 325-760, respectively. Mepazine affects viability of ABC-DLBCL cells by enhancing apoptosis.
体内研究：
Mepazine (16 mg/kg; intraperitoneal administration) interferes with growth and induces apoptosis of ABC-DLBCL cell line OCI-Ly10 in NOD/scid IL-2Rgnull (NSG) mice with a murine DLBCL xenogeneic tumor model. Daily administration of Mepazine strongly impairs the expansion of the ABC-DLBCL cell line OCI-Ly10.Animal Model:6- to 8-week-old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice with a murine DLBCL xenogeneic tumor model
Dosage:400 μg per animal (25 g), corresponding to approximately 16 mg/kg.
Administration:Intraperitoneal administration; started 1 or 12 days after transplantation and given continuously every 24 hr; daily application
Result:Daily administration strongly impaired the expansion of the ABC-DLBCL cell line OCI-Ly10.
体外研究：
Mepazine (5-20 μM; 4 days) causes a decrease of cell viability in the activated B cell subtype of diffuse large B cell lymphoma (ABCDLBCL) cells, without significantly affecting GCB-DLBCL cells.
Mepazine (Pecazine) is a potent and selective MALT1 protease inhibitor with IC50s of 0.83 and 0.42 μM for GSTMALT1 full length and GSTMALT1 325-760, respectively. Mepazine affects viability of ABC-DLBCL cells by enhancing apoptosis.
体内研究：
Mepazine (16 mg/kg; intraperitoneal administration) interferes with growth and induces apoptosis of ABC-DLBCL cell line OCI-Ly10 in NOD/scid IL-2Rgnull (NSG) mice with a murine DLBCL xenogeneic tumor model. Daily administration of Mepazine strongly impairs the expansion of the ABC-DLBCL cell line OCI-Ly10.Animal Model:6- to 8-week-old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice with a murine DLBCL xenogeneic tumor model
Dosage:400 μg per animal (25 g), corresponding to approximately 16 mg/kg.
Administration:Intraperitoneal administration; started 1 or 12 days after transplantation and given continuously every 24 hr; daily application
Result:Daily administration strongly impaired the expansion of the ABC-DLBCL cell line OCI-Ly10.
体外研究：
Mepazine (5-20 μM; 4 days) causes a decrease of cell viability in the activated B cell subtype of diffuse large B cell lymphoma (ABCDLBCL) cells, without significantly affecting GCB-DLBCL cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备